Tag: TSXV:IGX

October 9, 2019

IntelGenx Receives DSMB Recommendation for Phase 2a Trial

The Data Safety Monitoring Board completed its analysis of the company's Montelukast VersaFilm Phase 2a clinical trial of Alzheimer's Disease.
September 4, 2019

IntelGenx Partners with Tilray to Create Cannabis-infused Oral Strips

One pharmaceutical company is giving consumers the chance to experience the effects of cannabis in a new form: oral strips.
May 8, 2019

IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil

IntelGenx (TSXV:IGX, OTCQX:IGXT) has announced it has entered into a partnership with Aquestive Therapeutics (NASDAQ:AQST) to co-develop and commercialize Tadalafil...
May 1, 2019

IntelGenx Shares Creation of New US Patent

IntelGenx announced the issuance of a patent from the United States Patent and Trademark Office covering the design and manufacturing of topical...
January 30, 2019

IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT NDA

IntelGenx (TSXV:IGX,OTCQX:IGXT) a leading oral drug delivery company, today announced that the U.S. Food and Drug Administration has performed a...
January 23, 2019

IntelGenx Provides Update on Phase 2a Montelukast VersaFilm Clinical Trial

IntelGenx (TSXV:IGX,OTCQX:IGXT) a leading oral drug delivery company, provided an update on its Phase 2a study of Montelukast VersaFilm in...
November 20, 2018

IntelGenx Announces FDA’s Acceptance of Resubmission of New Drug Application for RIZAPORT

IntelGenx (TSXV:IGX) (OTCQX:IGXT) announced that its 505(b)(2) New Drug Application resubmission for RIZAPORT oral soluble film 10 mg for the treatment...